Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran

  • Mehdi Rezaee, Sadegh Izadi, Khosro Keshavarz, Afshin Borhanihaghighi, Ramin Ravangard
  • Journal of Medical Economics, December 2018, Taylor & Francis
  • DOI: 10.1080/13696998.2018.1560750

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Ramin Ravangard

join the fight against climate change

Our simple summaries of climate research help you take action

Read now